Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
84 hedge funds and large institutions have $81.8M invested in Jounce Therapeutics, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 31 increasing their positions, 21 reducing their positions, and 16 closing their positions.
48% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 21
0% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 16
1% less funds holding
Funds holding: 85 → 84 (-1)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
53% less capital invested
Capital invested by funds: $176M → $81.8M (-$93.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$841K |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$614K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$444K |
| 4 |
Two Sigma Investments
New York
|
+$378K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$370K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.59M |
| 2 |
CC
Casdin Capital
New York
|
-$2.44M |
| 3 |
Millennium Management
New York
|
-$1.97M |
| 4 |
BlackRock
New York
|
-$1.8M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.39M |
JNCE Hedge Fund Activity: Q4 2018 in Review
84 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q4 2018, worth a combined $81.8M — down 53% from $176M a quarter earlier.
Fund positioning in JNCE was balanced in Q4 2018: 16 funds opened new positions, 16 closed out, 31 added to existing stakes and 21 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $841K. The largest seller was Fidelity Investments, cutting an estimated $5.59M.
- 84 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q4 2018, down from 85 in Q3 2018.
- Funds reported $81.8M of Jounce Therapeutics, Inc. Common Stock stock for Q4 2018, down 53% quarter-over-quarter.
- 16 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q4 2018 and 16 closed out, a net change of 0 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q4 2018 was JP Morgan Chase, an estimated $841K added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q4 2018 was Fidelity Investments, an estimated $5.59M sold.
Based on aggregated 13F filings for Q4 2018.